Basic references for LigandTracer technology
LigandTracer technology was first described by Björke and Andersson in 2006. These two papers serve as suitable references for the basic functionality of LigandTracer:

Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area.
Björke H, Andersson K.
Appl Radiat Isot. 2006. 64(1):32-37.

Automated, high-resolution cellular retention and uptake studies in vitro.
Bjorke H, Andersson K.
Appl Radiat Isot. 2006. 64(8):901-905.

Scientific publications
Below is a list of, to our knowledge, all publications where LigandTracer has been used. If you do not find your publication in the list, please let us know!

G6Pase location in the endoplasmic reticulum: Implications on compartmental analysis of FDG uptake in cancer cells.
Scussolini M, Bauckneht M, Cossu V, Bruno S, Orengo AM, Piccioli P, Capitanio S, Yosifov N, Ravera S, Morbelli S, Piana M, Sambuceti G, Caviglia G, Marini C.
Sci Rep. 2019. 9:2794.

Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: In Vitro Evaluation on VEGFR2-positive Cell Lines.
Janousek J, Barta P, Novy Z, Zilkova K, Trejtnar F.
Anticancer Res. 2019. 39(2):735-744.

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.
Sci Rep. 2019. 9:655.

Obligatory role of endoplasmic reticulum in brain FDG uptake.
Cossu V, Marini C, Piccioli P, Rocchi A, Bruno S, Orengo AM, Emionite L, Bauckneht M, Grillo F, Capitanio S, Balza E, Yosifov N, Castellani P, Caviglia G, Panfoli I, Morbelli S, Ravera S, Benfenati F, Sambuceti G.
Eur J Nucl Med Mol Imaging. 2019. Epub ahead of print.

Comparative evaluation of two DARPin variants: effect of affinity, size and label on tumor targeting properties.
Deyev SM, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Orlova A, Tolmachev V.
Mol Pharm. 2019. Epub ahead of print.

ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.
Hlavnicková M, Kuchar M, Osicka R, Vanková L, Petroková H, Malý M, Cerný J, Arenberger P, Malý P.
Int J Mol Sci. 2018. 19(10):3089.

Protective nature of low molecular weight chitosan in a chitosan-Amphotericin B nanocomplex - A physicochemical study.
Krishnan AK, Pant T, Sankaranarayan S, Stenberg J, Jain R, Dandekar P.
Materials Science and Engineering: C. 2018. 93:472-482

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.
Theranostics. 2018. 8(16):4462-4476.

Time-lapse imaging of molecular evolution by high-throughput sequencing.
Nguyen Quang N, Bouvier C, Henriques A, Lelandais B, Ducongé F.
Nucleic Acids Research. 2018. 46(15):7480-7494.

SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [18F]FE@SNAP and [11C]SNAP-7941.
Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vraka C, Balber T, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M.
Mol Imaging Biol. 2018. Epub ahead of print.

A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter.
Vraka C, Dumanic M, Racz T, Pichler F, Philippe C, Balber T, Klebermass EM, Wagner KH, Hacker M, Wadsak W, Mitterhauser M.
Nucl Med Biol. 2018. 60:29-36.

Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study.
Buschiazzo A, Cossu V, Bauckneht M, Orengo A, Piccioli P, Emionite L, Bianchi G, Grillo F, Rocchi A, Di Giulio F, Fiz F, Raffaghello L, Nobili F, Bruno S, Caviglia G, Ravera S, Benfenati F, Piana M, Morbelli S, Sambuceti G, Marini C.
EJNMMI Res. 2018 Jun 11;8(1):44.

Helicobacter pylori adhesin HopQ disrupts trans dimerization in human CEACAMs.
Moonens K, Hamway Y, Neddermann M, Reschke M, Tegtmeyer N, Kruse T, Kammerer R, Mejías?Luque R, Singer BB, Backert S, Gerhard M, Remaut H.
EMBO J. 2018. 37(13).

Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.
Haylock AK, Nilvebrant J, Mortensen A, Velikyan I, Nestor M, Falk R.
Oncotarget. 2017. 8(39):65152-65170.

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC, Spiegelberg D, Haylock AK, Lundqvist H, Nestor M.
Int J Oncol. 2018. 52(6):1875-1885.

Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse.
Nordling S, Brännström J, Carlsson F, Lu B, Salvaris E, Wanders A, Buijs J, Estrada S, Tolmachev V, Cowan PJ, Lorant T, Magnusson PU.
Scientific Reports. 2018. 8: 5220.

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.
Chekkat N, Lombardo CM, Seguin C, Lechner M-C, Dufour F, Nominé Y, De Giorgi M, Frisch B, Micheau O, Guichard G, Altschuh D, Fournel S.
Oncotarget. 2018. 9:15566-15578.

Detecting ligand interactions in real time on living bacterial cells.
Crispim Encarnação J, Schulte T, Achour A, Björkelund H, Andersson K.
Appl Microbiol Biot. 2018. 102(9):4193-4201.

[18F]FEPPA: Improved automated radiosynthesis, binding affinity and preliminary in vitro evaluation in colorectal cancer.
Berroterán-Infante N, Balber T, Fürlinger P, Bergmann M, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W.
ACS Med Chem Lett. 2018. 9(3):177-181.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.
Br J Haematol. 2018. 180(6):808-820.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
Garousi J, Lindbo S, Mitran B, Buijs J, Vorobyeva A, Orlova A, Tolmachev V, Hober S.
Scientific Reports. 2017. 7(1):14780.

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.
Honarvar H, Calce E, Doti N, Langella E, Orlova A, Buijs J, D'Amato V, Bianco R, Saviano M, Tolmachev V, De Luca S.
Scientific Reports. 2018. 8(1):2998.

Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.
Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom J, Orlova A, Tolmachev V, Decristoforo C.
Mol Pharm. 2018. 15(1):175-185.

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
Mitran B, Thisgaard H, Rosenström U, Dam JH, Larhed M, Tolmachev V, Orlova A.
Contrast Media Mol Imaging. 2017. Volume 2017.

A novel real-time proximity assay for characterizing multiple receptor interactions on living cells.
Bondza S, Björkelund H, Nestor M, Andersson K, Buijs J.
Anal Chem. 2017. 89(24):13212-13218

Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials.
Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E.
Oncotarget. 2017. 8:83128-83141.

Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label.
Lindbo S, Garousi J, Mitran B, Altai M, Buijs J, Orlova A, Hober S, Tolmachev V.
J Nucl Med. 2018. 59(1):93-99

Impact of assay temperature on antibody binding characteristics in living cells: A case study.
Crispim Encarnação J, Barta P, Fornstedt T, Andersson K.
Biomed Rep. 2017. 7(5):400-406

Novel strategy utilizing extracellular cysteine-rich domain of membrane receptor for constructing D-peptide mediated targeted drug delivery systems: A case study on Fn 14.
Lie Z, Xie J, Peng S, Liu S, Wang Y, Lu W, Shen J, Li C.
Bioconjug Chem. 2017. 28(8):2167-2179

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J, Andersson KG, Dam JH, Olsen BB, Mitran B, Orlova A, Buijs J, Ståhl S, Löfblom J, Thisgaard H, Tolmachev V.
Scientific Reports. 2017. 7(1):5961

EGF-targeting lipodisks for specific delivery of poorly water-soluble anticancer agents to tumour cells.
Ahlgren S, Fondell A, Gedda L, Edwards K.
RSC Adv. 2017. 7: 22178-22186.

Inducible epitope imprinting: 'generating' the required binding site in membrane receptors for targeted drug delivery.
Liu S, Bi Q, Long Y, Li Z, Bhattacharyya S, Li C.
Nanoscale. 2017. 9:5394-5397

Targeting molecules for diagnostics of Head and Neck squamous cell carcinoma.
Haylock AK.
PhD thesis at Uppsala University.

Real-time characterization of antibody binding to receptors on living immune cells.
Bondza S, Foy E, Brooks J, Andersson K, Robinson J, Richalet P, Buijs J.
Front. Immunol. 2017. 8(455).

New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics.
Zeilinger M, Pichler F, Nics L, Wadsak W, Spreitzer H, Hacker M, Mitterhauser M.
EJNMMI Res. 2017. 7(1):22.

Helicobacter pylori adapts to chronic infection and gastric disease via pH-Responsive BabA-mediated adherence.
Bugaytsova JA et al.
Cell Host Microbe. 2017. 21(3):376-389.

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.
Bass TZ, Rosestedt M, Mitran B, Frejd FY, Löfblom J, Tolmachev V, Ståhl S, Orlova A.
Scientific Reports. 2017. 7:43118.

Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.
Braig D, Nero T L, Koch HG, Kaiser B, Wang X, Thiele JR, Morton CJ, Zeller J, Kiefer J, Potempa LA, Mellett NA, Miles LA, Du XJ, Meikle PJ, Huber-Lang M, Stark GB, Parker MW, Peter K, Eisenhardt SU.
Nat Commun. 2017. 8:14188.

Guided growth of auditory neurons: Bioactive particles towards gapless neural - Electrode interface.
Li H, Edin F, Hayashi H, Gudjonsson O, Danckwardt-Lillieström N, Engqvist H, Rask-Andersen H, Xia W.
Biomaterials. 2017. 122:1-9.

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator
Andersson KG, Oroujeni M, Garousi J, Mitran B, Ståhl S, Orlova A, Löfblom J, Tolmachev V.
Int J Oncol. 2016. 49(6):2285-2293.

In vitro evaluation of concentration, labeling effectiveness and stability for 131I-labeled radioimmunoassay ligand using real-time detection technology.
Barta P, Janousek J, Zilkova K, Trejtnar F.
J Labelled Comp Radiopharm. 2017. 60(1):80-86.

Influence of the N-terminal composition on targeting properties of radiometal-labeled anti-HER2 scaffold protein ADAPT6.
Garousi J, Lindbo S, Honarvar H, Velletta J, Mitran B, Altai M, Orlova A, Tolmachev V, Hober S.
Bioconjugate Chem. 2016. 27(11):2678-2688.

Biophysics in drug discovery: impact, challenges and opportunities.
Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H.
Nat Rev Drug Discov. 2016. 15(10):679-698.

Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Garousi J, Honarvar H, Andersson KG, Mitran B, Orlova A, Buijs J, Löfblom J, Frejd FY, Tolmachev V.
Mol Pharm. 2016. 13(11):3676-3687.

Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M.
BMC Immunol. 2016. 17(1):23.

Vascular interactions in innate immunity and immunothrombosis: Models of endothelial protection.
Nordling S.
PhD thesis at Uppsala University.

Strategies in cochlear nerve regeneration, guidance and protection: Prospects for future cochlear implants.
Edin F.
PhD thesis at Uppsala University.

PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J, Andersson KG, Mitran B, Pichl ML, Ståhl S, Orlova A, Löfblom J, Tolmachev V.
Int J Oncol. 2016. 48(4):1325-1332.

Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.
Haylock AK, Spiegelberg D, Mortensen AC, Selvaraju RK, Nilvebrant J, Eriksson O, Tolmachev V, Nestor MV.
Int J Oncol. 2016. 48(2):461-470.

Influence of histidine-containing tags on the biodistribution of ADAPT scaffold proteins.
Lindbo S, Garousi J, Åstrand M, Honarvar H, Orlova A, Hober S, Tolmachev V.
Bioconjug Chem. 2016. 27(3):716-726.

Cellulose nanofiber-titania nanocomposites as potential drug delivery systems for dermal applications.
Galkina OL, Ivanov VK, Agafonov AV, Seisenbaeva GA, Kessler VG.
J Mater Chem B. 2015. 3: 1688-1698.

Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors.
Honarvar H, Westerlund K, Altai M, Sandström M, Orlova A, Tolmachev V, Eriksson Karlström A.
Theranostics. 2016. 6(1): 93-103.

In vivo imaging of natural killer cell trafficking in tumors.
Galli F, Rapisarda AS, Stabile H, Malviya G, Manni I, Bonanno E, Piaggio G, Gismondi A, Santoni A, Signore A.
J Nucl Med. 2015. 56(10):1575-1580.

A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties.
Spiegelberg D, Stenberg J, Haylock AK, Nestor M.
Nucl Med Biol. 2016. 43:12-18.

ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers.
Garousi J, Lindbo S, Nilvebrant J, Åstrand M, Buijs J, Sandström M, Honarvar H, Orlova A, Tolmachev V, Hober S.
Cancer Res. 2015. 75(20):4364-4371.

Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861.
Gilabert-Oriol R, Weng A, Trautner A, Weise C, Schmid D, Bhargava C, Niesler N, Wookey PJ, Fuchs H, Thakur M.
Biochem Pharmacol. 2015. 97(3):247-255.

Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer® devices.
Varasteh Z, Orlova A.
J Radioanal Nucl Chem. 2015. 304(2): 823-828.

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule.
Honarvar H, Garousi J, Gunneriusson E, Höidén-Guthenberg I, Altai M, Widström C, Tolmachev V, Frejd FY.
Int J Oncol. 2015. 46(2):513-520

Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B, Altai M, Hofström C, Honarvar H, Sandström M, Orlova A, Tolmachev V, Gräslund T.
Amino Acids. 2015. 47(2):303-315.

99mTc-Labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.
Galli F, Manni I, Piaggio G, Balogh L, Weintraub BD, Szkudlinski MW, Fremont V, Dierckx RAJO, Signore A.
Thyroid. 2014. 24(8):1297-1308.

Conjugation effects on antibody-drug conjugates: Evaluation of interaction kinetics in real time on living cells.
Bondza S, Stenberg J, Nestor M, Andersson K, Björkelund H.
Mol Pharm. 2014. 11(11):4154-4163

188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: Preclinical assessment.
Altai M, Wållberg H, Honarvar H, Strand J, Orlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand S, Lubberink M, Ståhl S, Tolmachev V.
J Nucl Med. 2014. 55(11):1842-1848.

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re.
Altai M, Honarvar H, Wållberg H, Strand J, Varasteh Z, Rosestedt M, Orlova A, Dunås F, Sandström M, Löfblom J, Tolmachev V, Ståhl S.
Eur J Med Chem. 2014. 87:519-528.

Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay.
Barta P, Volkova, Dascalu A, Spiegelberg D, Trejtnar F, Andersson K.
J Pharmacol Toxicol Methods. 2014. 70(2):145-151.

The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
Varasteh Z, Rosenström U, Velikyan I, Mitran B, Altai M, Honarvar H, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.
Molecules. 2014. 19(7):10455-10472.

Exploring time-resolved characterization of the heterogeneity and dynamics of ligand-receptor interactions on living cells.
Barta P, Andersson K, Trejtnar F, Buijs J.
J Anal Onc. 2014. 3(2): 94-104.

Evaluation of a 99mTc-labelled meso-bisphenylporphyrin as a tumour image agent.
Santos PM, Laranjo M, Serra AC, Abrantes AM, Piñeiro M, Casalta-Lopes J, Trindade D, Maia J, Rocha-Gonsalves A, Botelho MF.
J Labelled Comp Radiopharm. 2014. 57(3):141-147.

Automated functional characterization of radiolabeled antibodies: a time-resolved approach.
Wang E, Björkelund H, Mihaylova D, Hagemann UB, Karlsson J, Malmqvist M, Buijs J, Abrahmsén L, Andersson K.
Nucl Med Commun. 2014. 35(7):767-776.

The 19S deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
Wang X, Stafford W, Mazurkiewicz M, Fryknas M, Brjnic S, Zhang X, Gullbo J, Larsson R, Arner E, D'Arcy P, Linder S.
Mol Pharmacol. 2014. 85(6):932-945.

NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation.
Koch S, van Meeteren LA, Morin E, Testini C, Weström S, Björkelund H, Le Jan S, Adler J, Berger P, Claesson-Welsh L.
Dev Cell. 2014. 28(6):633-646

Imaging of platelet-derived growth factor receptor β Expression in glioblastoma xenografts using affibody molecule 111in-DOTA-Z09591.
Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A.
J Nucl Med. 2014. 55(2):294-300.

Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods.
Dubois L, Andersson K, Asplund A, Björkelund H.
BMC Res Notes. 2013. 6(1):542.

Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6.
Stenberg J, Spiegelberg D, Karlsson H, Nestor M.
Nucl Med Biol. 2014. 41(2):140-147.

Preclinical development of imaging agents for HER2 expression in prostate cancer using radiolabeled affibody molecules.
Malmberg J.
PhD thesis at Uppsala University.

Detecting ligand interactions with G protein-coupled receptors in real-time on living cells.
Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Björkelund H.
Biochem Biophys Res Commun. 2013. 441(4):820-824.

CD14 mediates binding of high doses of LPS but is dispensable for TNF-a production.
Borzecka K, Plóciennikowska A, Björkelund H, Sobota A, Kwiatkowska K.
Mediat Inflamm. 2013:824919

Evaluation of real-time immunohistochemistry and Interaction Map as an alternative objective assessment of HER2 expression in human breast cancer tissue.
Gedda L, Björkelund H, Lebel L, Asplund A, Dubois L, Wester K, Penagos N, Malmqvist M, Andersson K.
Appl Immunohistochem Mol Morphol. 2013. 21(6):497-505.

Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Sandström M, Selvaraju RK, Malmberg J, Tolmachev V, Orlova A.
Bioconjug Chem. 2013. 24(7):1144-1153.

Human monoclonal antibodies, chapter 16: Methods for radiolabelling of monoclonal antibodies.
Tolmachev V, Orlova A, Andersson K.
Springer Protocols. 2013. Vol. 1060.

Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation.
Autio A, Vainio PJ, Suilamo S, Mali A, Vainio J, Saanijoki T, Noponen T, Ahtinen H, Luoto P, Teräs M, Jalkanen S, Roivainen A.
J Nucl Med. 2013. 54(8):1315-1319.

Novel methods for analysis of heterogeneous protein-cell interactions: Resolving how the epidermal growth factor binds to its receptor.
Björkelund H.
PhD thesis at Uppsala University.

Bringing time into molecular and cellular biology.
Andersson, K.
J Anal Onc. 2013. 2: 65-68.

Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging.
Honarvar H, Jokilaakso N, Andersson K, Malmberg J, Rosik D, Orlova A, Karlström AE, Tolmachev V, Järver P.
Nucl Med Biol. 2013. 40(3):378-386.

The HER2-binding affibody molecule (ZHER2:342)2 increases radiosensitivity in SKBR-3 cells.
Ekerljung L, Lennartsson J, Gedda L.
PLoS ONE. 2012. 7(11): e49579.

Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.
Björkelund H, Gedda L, Malmqvist M, Andersson K.
Mol Clin Onc. 2013. 1: 343-352.

Deciphering complex protein interaction kinetics using Interaction Map.
Altschuh D, Björkelund H, Strandgård J, Choulier L, Malmqvist M, Andersson K.
Biochem Biophys Res Commun. 2012. 428(1):74-9.

Selection and in vitro characterization of human CD44v6-binding antibody fragments.
Nilvebrant J, Kuku G, Björkelund H, Nestor M.
Biotechnol Appl Biochem. 2012. 59(5): 367-380.

A comparison of in vitro methods for determining the membrane receptor expression in cell lines.
Novy Z, Barta P, Mandikova J, Laznicek M, Trejtnar F.
Nucl Med Biol. 2012. 39(7):893-6.

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.
Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L.
Bioconjug Chem. 2012. 23(9):1802-11.

In vitro 2-Deoxy-2-[18F]fluoro-D-glucose uptake: practical considerations.
Mertens K, Mees G, Lambert B, Van de Wiele C, Goethals I.
Cancer Biother Radiopharm. 2012. 27(3):183-8.

Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation.
Rouzet F, Bachelet-Violette L, Alsac JM, Suzuki M, Meulemans A, Louedec L, Petiet A, Jandrot-Perrus M, Chaubet F, Michel JB, Le Guludec D, Letourneur D.
J Nucl Med. 2011. 52(9):1433-40.

Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.
Barta P, Malmberg J, Melicharova L, Strandgård J, Orlova A, Tolmachev V, Laznicek M, Andersson K.
Int J Oncol. 2012. 40(5):1677-82.

Adenovirus with hexon Tat-PTD modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M.
J Virol. 2011. 85(24):13114-13123

Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF.
Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K.
PLoS ONE. 2011. 6(9): e24739.

Surface functionalization of the metal oxide nanoparticles with biologically active molecules containing phosphonate moieties. Case study of BaTiO3.
Pazik R, Andersson R, Kepinski L, Nedelec JM, Kessler VG, Seisenbaeva GA.
J Phys Chem C. 2011. 115 (20): 9850-9860.

Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
Björkelund H, Gedda L, Andersson K.
PLoS ONE. 2011. 6(1): e16536.

Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS.
Weeks AJ, Jauregui-Osoro M, Cleij M, Blower JE, Ballinger JR, Blower PJ.
Nucl Med Commun. 2011. 32(2):98-105.

Antibody-antigen interactions: What is the required time to equilibrium?
Andersson K, Björkelund H, Malmqvist M.
Nature Preceedings. 2010.

Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression.
Malviya G, de Vries EF, Dierckx RA, Signore A.
Mol Imaging Biol. 2011. 13(5):930-939.

Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells.
Wang X, Albertioni F.
Nucleosides Nucleotides Nucleic Acids. 2010. 29(4-6):414-418.

Real-time immunohistochemistry analysis of embedded tissue.
Gedda L, Björkelund H, Andersson K.
Appl Radiat Isot. 2010. 68(12):2372-2376.

Avoiding false negative results in specificity analysis of protein-protein interactions.
Björkelund H, Gedda L, Andersson K.
J Mol Recognit. 2011. 24(1):81-89.

Biomimetic synthesis of hierarchically porous nanostructured metal oxide microparticles-potential scaffolds for drug delivery and catalysis.
Seisenbaeva GA, Moloney MP, Tekoriute R, Hardy-Dessources A, Nedelec JM, Gun'ko YK, Kessler VG.
Langmuir. 2010. 26(12):9809-9817.

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY, Ståhl S.
Biotechnol Appl Biochem. 2009. 54(2):121-131.

Identification and properties of a receptor for the invertebrate cytokine astakine, involved in hematopoiesis.
Lin X, Kim YA, Lee BL, Söderhäll K, Söderhäll I.
Exp Cell Res. 2009. 315(7):1171-1180.

Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay.
Nestor M, Andersson K, Lundqvist H.
J Mol Recognit. 2008. 21(3):179-183.

Real-time viability assay based on 51Cr retention in adherent cells.
Vennström L, Bysell C, Björkelund H, Lundqvist H, Andersson K.
BioTechniques. 2008. 44(2):237-240.

The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis.
Fransson J, Borrebaeck, CA,
Int J Cancer. 2006. 119(10):2492-2496.